Literature DB >> 29481902

Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma.

Katja Maurus1, Silke Appenzeller2, Sabine Roth3, Jochen Kuper4, Simone Rost5, Svenja Meierjohann6, Panagiota Arampatzi7, Matthias Goebeler8, Andreas Rosenwald3, Eva Geissinger3, Marion Wobser8.   

Abstract

Primary cutaneous marginal zone lymphoma (PCMZL) represents an indolent subtype of non-Hodgkin lymphoma that is clinically characterized by slowly growing skin tumors with a very low propensity for systemic dissemination. The underlying genetic basis of PCMZL has not been comprehensively elucidated. To gain deeper insight into the molecular pathogenesis of PCMZL, we performed hybridization-based panel sequencing of 38 patients with well-characterized PCMZL. In 32 of the 38 patients, we identified genetic alterations within 39 selected target genes. The most frequently detected alterations (24/38 patients, 63.2%) affected the FAS gene, of which 22 patients harbored alterations, which affect the functionally relevant death domain of the apoptosis-regulating FAS/CD95 protein in a dominant-negative manner. In addition, we identified highly recurrent mutations in three other genes, namely SLAMF1, SPEN, and NCOR2. Our molecular data suggest that apoptosis defects provide the molecular basis of the observed clinical features of PCMZL, which commonly presents with only slowly growing skin tumors, reflecting its invariably indolent behavior. From a diagnostic point of view, highly recurrent FAS mutations in PCMZL presumably separate this indolent lymphoma entity from pseudolymphoma, and this adds adjunctive discriminatory features at a molecular level.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29481902     DOI: 10.1016/j.jid.2018.02.015

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

Review 1.  Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas.

Authors:  Amanda Krenitsky; Skylar Klager; Leigh Hatch; Carlos Sarriera-Lazaro; Pei Ling Chen; Lucia Seminario-Vidal
Journal:  Am J Clin Dermatol       Date:  2022-07-19       Impact factor: 6.233

Review 2.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Authors:  Rita Alaggio; Catalina Amador; Ioannis Anagnostopoulos; Ayoma D Attygalle; Iguaracyra Barreto de Oliveira Araujo; Emilio Berti; Govind Bhagat; Anita Maria Borges; Daniel Boyer; Mariarita Calaminici; Amy Chadburn; John K C Chan; Wah Cheuk; Wee-Joo Chng; John K Choi; Shih-Sung Chuang; Sarah E Coupland; Magdalena Czader; Sandeep S Dave; Daphne de Jong; Ming-Qing Du; Kojo S Elenitoba-Johnson; Judith Ferry; Julia Geyer; Dita Gratzinger; Joan Guitart; Sumeet Gujral; Marian Harris; Christine J Harrison; Sylvia Hartmann; Andreas Hochhaus; Patty M Jansen; Kennosuke Karube; Werner Kempf; Joseph Khoury; Hiroshi Kimura; Wolfram Klapper; Alexandra E Kovach; Shaji Kumar; Alexander J Lazar; Stefano Lazzi; Lorenzo Leoncini; Nelson Leung; Vasiliki Leventaki; Xiao-Qiu Li; Megan S Lim; Wei-Ping Liu; Abner Louissaint; Andrea Marcogliese; L Jeffrey Medeiros; Michael Michal; Roberto N Miranda; Christina Mitteldorf; Santiago Montes-Moreno; William Morice; Valentina Nardi; Kikkeri N Naresh; Yasodha Natkunam; Siok-Bian Ng; Ilske Oschlies; German Ott; Marie Parrens; Melissa Pulitzer; S Vincent Rajkumar; Andrew C Rawstron; Karen Rech; Andreas Rosenwald; Jonathan Said; Clémentine Sarkozy; Shahin Sayed; Caner Saygin; Anna Schuh; William Sewell; Reiner Siebert; Aliyah R Sohani; Reuben Tooze; Alexandra Traverse-Glehen; Francisco Vega; Beatrice Vergier; Ashutosh D Wechalekar; Brent Wood; Luc Xerri; Wenbin Xiao
Journal:  Leukemia       Date:  2022-06-22       Impact factor: 12.883

Review 3.  Recent advances in cutaneous lymphoma-implications for current and future classifications.

Authors:  J R Goodlad; L Cerroni; S H Swerdlow
Journal:  Virchows Arch       Date:  2022-10-24       Impact factor: 4.535

4.  Epstein-Barr Virus-negative Marginal Zone Lymphoma as an Uncommon Form of Monomorphic Posttransplant Lymphoproliferative Disorder.

Authors:  Pallavi Galera; Richard Flavin; Natasha M Savage; Annapurna Saksena; Shunyou Gong; Huan-You Wang; Niall Swan; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2020-10       Impact factor: 6.298

5.  Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue.

Authors:  Bryan Rea; Yen-Chun Liu; Alanna Maguire; Lorinda A Soma; Chris M Bacon; Michael G Bayerl; Molly H Smith; Michael T Barrett; Steven H Swerdlow; Sarah E Gibson
Journal:  Mod Pathol       Date:  2021-12-24       Impact factor: 8.209

6.  Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.

Authors:  Thomas Menter; Alexandar Tzankov; Visar Vela; Darius Juskevicius; Stefan Dirnhofer
Journal:  Virchows Arch       Date:  2021-09-08       Impact factor: 4.064

7.  Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.

Authors:  Xiaolong Alan Zhou; Jingyi Yang; Kimberly G Ringbloom; Maria Estela Martinez-Escala; Kristen E Stevenson; Alexander T Wenzel; Damiano Fantini; Haley K Martin; Andrea P Moy; Elizabeth A Morgan; Shannon Harkins; Christian N Paxton; Bo Hong; Erica F Andersen; Joan Guitart; David M Weinstock; Lorenzo Cerroni; Jaehyuk Choi; Abner Louissaint
Journal:  Blood Adv       Date:  2021-02-09

8.  High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.

Authors:  V Pillonel; D Juskevicius; C K Y Ng; A Bodmer; A Zettl; D Jucker; S Dirnhofer; A Tzankov
Journal:  Leukemia       Date:  2018-02-28       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.